Last reviewed · How we verify
Arformoterol Tartrate Inhalation Solution
Arformoterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow.
Arformoterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow. Used for Chronic obstructive pulmonary disease (COPD) maintenance treatment, Asthma maintenance treatment.
At a glance
| Generic name | Arformoterol Tartrate Inhalation Solution |
|---|---|
| Also known as | Brovana, Brovana®, BROVANA, (R,R)-formoterol, (R,R-)formoterol |
| Sponsor | Sumitomo Pharma America, Inc. |
| Drug class | Long-acting beta-2 adrenergic agonist (LABA) |
| Target | Beta-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Pulmonology |
| Phase | FDA-approved |
Mechanism of action
Arformoterol tartrate is the active (R,R)-enantiomer of formoterol, a selective beta-2 adrenergic receptor agonist. Upon inhalation, it binds to beta-2 receptors on bronchial smooth muscle, activating adenylyl cyclase and increasing intracellular cAMP, which leads to smooth muscle relaxation and sustained bronchodilation. As a long-acting formulation, it provides extended therapeutic effect over 12 hours or longer.
Approved indications
- Chronic obstructive pulmonary disease (COPD) maintenance treatment
- Asthma maintenance treatment
Common side effects
- Tremor
- Headache
- Palpitations
- Muscle cramps
- Nervousness
- Tachycardia
Key clinical trials
- A Study of Arformoterol Tartrate Inhalation Solution and Tiotropium Bromide on Re-hospitalization in Chronic Obstructive Pulmonary Disease (COPD) Subjects (PHASE4)
- Safety Study of Arformoterol Tartrate Inhalation Solution in Chronic Obstructive Pulmonary Disease (COPD) Subjects (PHASE3)
- A Pivotal Study of the Safety and Effectiveness of Arformoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (PHASE3)
- Assessment of Arformoterol for Chronic Obstructive Pulmonary Disease (COPD) Using Hyperpolarized 3He MRI (NA)
- Sunovion Brovana Versus Serevent Inspiratory Capacity High Resolution Computed Tomography (PHASE4)
- Efficacy Safety Study of Arformoterol/Tiotropium Combination Versus Either Therapy Alone in Chronic Obstructive Pulmonary Disease (COPD) (PHASE4)
- Safety and Efficacy of Arformoterol Tartrate Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease (PHASE3)
- Determine the Safety and Efficacy of (R,R)-Formoterol in the Treatment of Subjects With COPD (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: